The announcement was made during trading hours today, 11 April 2016.

Meanwhile, the S&P BSE Sensex was down 20.98 points or 0.09% at 24,652.86.

On BSE, so far 7.80 lakh shares were traded in the counter as against average daily volume of 88,000 shares in the past two weeks. The stock hit a high of Rs 43.90 and a low of Rs 39.45 so far during the day. The stock had hit a 52-week high of Rs 75.30 on 6 August 2015. The stock had hit a 52-week low of Rs 32.60 on 29 February 2016.

Orchid Pharma said it received the Establishment inspection report (EIR) from US Food and Drug Administration (USFDA) based on the successful inspection closure for the active pharmaceutical ingredient (API) manufacturing facility located in Alathur at Kancheepuram District in Tamil Nadu, India. The facility was inspected by USFDA in August 2015.

Orchid Pharma reported net loss of Rs 94.02 crore in Q3 December 2015 as against net loss of Rs 120.09 crore in Q3 December 2014. Net sales rose 26.96% to Rs 201.89 crore in Q3 December 2015 ove Q3 December 2014.

Orchid Pharma is a vertically integrated company spanning the entire pharmaceutical value chain from discovery to delivery with established credentials in research, manufacturing and marketing.